Skip to main content
. 2018 Nov 26;19:77. doi: 10.1186/s40360-018-0264-8

Table 3.

Percentage of patients with adverse effects observed in the COMPARZ study

ADVERSE EFFECT PAZOPANIB SUNITINIB
Fatigue
 Any grade 50% 63%
 Grade 3–4 10% 17%
Hand-foot syndrome
 Any grade 29% 50%
 Grade 3–4 6% 11%
Stomatitis
 Any grade 14% 27%
ALTb 60% 43%
Fatal AEas 2% 3%
Fatal treatment-related AEs 3 cases 8 cases

aAE: adverse events; bALT: alanine aminotransferase